Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Operating Margin: 2017-2025

Historic Operating Margin for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to -546.15%.

  • Arcus Biosciences' Operating Margin fell 32740.00% to -546.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -156.25%, marking a year-over-year decrease of 3534.00%. This contributed to the annual value of -127.91% for FY2024, which is 16269.00% up from last year.
  • Per Arcus Biosciences' latest filing, its Operating Margin stood at -546.15% for Q3 2025, which was down 10,823.08% from -5.00% recorded in Q2 2025.
  • Arcus Biosciences' 5-year Operating Margin high stood at 79.25% for Q4 2021, and its period low was -825.87% during Q3 2021.
  • In the last 3 years, Arcus Biosciences' Operating Margin had a median value of -286.21% in 2023 and averaged -278.03%.
  • The largest annual percentage gain for Arcus Biosciences' Operating Margin in the last 5 years was 178,812bps (2021), contrasted with its biggest fall of 82,828bps (2021).
  • Over the past 5 years, Arcus Biosciences' Operating Margin (Quarterly) stood at 79.25% in 2021, then plummeted by 29,689bps to -217.65% in 2022, then slumped by 7,590bps to -293.55% in 2023, then tumbled by 10,261bps to -396.15% in 2024, then plummeted by 32,740bps to -546.15% in 2025.
  • Its Operating Margin was -546.15% in Q3 2025, compared to -5.00% in Q2 2025 and -435.71% in Q1 2025.